-+ 0.00%
-+ 0.00%
-+ 0.00%

Vistagen Therapeutics Earnings Report: Q3 Overview

Benzinga·02/12/2026 21:32:07
Listen to the news

Vistagen Therapeutics (NASDAQ:VTGN) just disclosed its Q3 earnings on Thursday, February 12, 2026 at 04:20 PM.

Here's a brief overview of the earnings report.

Earnings

Vistagen Therapeutics missed estimated earnings by -15.38%, reporting an EPS of $-0.45 versus an estimate of $-0.39.

Revenue was up $69 thousand from the same period last year.

Past Earnings Performance

The company missed on EPS by $0.07 in the previous quarter, leading to a 0.0% increase share price change the next day.

Here's a look at Vistagen Therapeutics's past performance:

Quarter Q2 2026 Q1 2026 Q4 2025 Q3 2025
EPS Estimate -0.47 -0.45 -0.49 -0.52
EPS Actual -0.54 -0.47 -0.44 -0.46
Revenue Estimate 339K 389K 209K 179K
Revenue Actual 258K 244K -15K 234K

To track all earnings releases for Vistagen Therapeutics visit their earnings calendar here.

This article was generated by Benzinga's automated content engine and reviewed by an editor.